A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A

Usui Kazuhiro; Sugawara Shunichi; Nishitsuji Masaru; Fujita Yuka; Inoue Akira; Mouri Atsuto; Watanabe Hiroshi; Sakai Hiroshi; Kinoshita Ichiro; Ohhara Yoshihito; Maemondo Makoto; Kagamu Hiroshi; Hagiwara Koichi; Kobayashi Kunihiko

首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A

【24h】

A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A

机译：非鳞状非小细胞肺癌患者贝伐单抗与恶性胸膜肺癌患者的贝伐单抗的II研究：东北日本研究组试验NEJ013A

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Vascular endothelial growth factor (VEGF) plays a pivotal role in the pathogenesis of malignant pleural effusion (MPE). Here, a multicenter phase II trial to evaluate bevacizumab in non-squamous non-small cell lung carcinoma patients with MPE was conducted.

机译：背景：血管内皮生长因子（VEGF）在恶性胸腔积液（MPE）的发病机制中起着枢轴作用。这里，进行多中心期II试验，用于评估NE鳞状非小细胞肺癌患者MPE患者的贝伐单抗。

著录项

来源
《Lung cancer: Journal of the International Association for the Study of Lung Cancer》 |2016年第null期|共6页
作者
Usui Kazuhiro; Sugawara Shunichi; Nishitsuji Masaru; Fujita Yuka; Inoue Akira; Mouri Atsuto; Watanabe Hiroshi; Sakai Hiroshi; Kinoshita Ichiro; Ohhara Yoshihito; Maemondo Makoto; Kagamu Hiroshi; Hagiwara Koichi; Kobayashi Kunihiko;
展开▼
作者单位

NIT Med Ctr Tokyo Div Respirol Shinagawa Ku 5-9-22 Higashigotanda Tokyo Japan;

Sendai Kousei Hosp Dept Pulm Med Sendai Miyagi Japan;

Ishikawa Prefectural Cent Hosp Dept Resp Med Kanazawa Ishikawa Japan;

Asahikawa Med Ctr Natl Hosp Org Dept Resp Med Asahikawa Hokkaido Japan;

Tohoku Univ Hosp Dept Resp Med Sendai Miyagi Japan;

Natl Hosp Org Disaster Med Ctr Dept Pulmonol Tokyo Japan;

Saka Gen Hosp Dept Resp Med Shiogama Miyagi Japan;

Saitama Canc Ctr Dept Thorac Oncol Ina Saitama Japan;

Hokkaido Univ Grad Sch Med Dept Med Oncol Sapporo Hokkaido 060 Japan;

KKR Sapporo Med Ctr Dept Med Oncol Sapporo Hokkaido Japan;

Miyagi Canc Ctr Dept Resp Med Natori Miyagi Japan;

Niigata Univ Med &

Dent Hosp Dept Resp Med &

Infect Dis Niigata 95021 Japan;

Jichi Univ Saitama Med Ctr Dept Comprehens Med 1 Shimotsuke Tochigi Japan;

Saitama Med Univ Saitama Int Med Ctr Dept Resp Med Moroyama Saitama Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Malignant pleural effusions; Bevacizumab; Non-small cell lung cancer; Lung cancer; Pleurodesis; Pemetrexed;

机译：恶性胸膜湿度;贝伐单抗;非小细胞肺癌;肺癌;胸膜瘤;Pemetrexed;
入库时间 2022-08-20 04:56:58

相似文献

外文文献
中文文献
专利

1. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A [J] . Usui Kazuhiro, Sugawara Shunichi, Nishitsuji Masaru, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2016,第Null期

机译：贝伐单抗联合卡铂培美曲塞治疗非鳞状非小细胞肺癌恶性胸腔积液的II期临床研究：东北日本研究组试验NEJ013A
2. Bevacizumab plus chemotherapy in nonsquamous non‐small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B [J] . Rintaro Noro, Kunihiko Kobayashi, Jiro Usuki, Thoracic cancer. . 2020,第7期

机译：Bevacizumab Plus化疗在非调节非小细胞肺癌患者的恶性胸膜积液因管排水或胸膜渗透：II期研究东北日本研究组试验NEJ013B
3. Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study) [J] . Hiranuma Osamu, Uchino Junji, Yamada Tadaaki, Clinical lung cancer . 2019,第3期

机译：OSIMERTINIB与未处理表皮生长因子受体突变的非小细胞肺癌和恶性胸腔和/或心包积液（螺旋II学习）患者患者II型试验的基础试验
4. Quantitative proteomics studies of the patient-matched normal and non-small cell lung cancer cell lines [C] . Yue Chen, Hua Xu, Yingming Zhao American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2012

机译：患者匹配正常和非小细胞肺癌细胞系的定量蛋白质组学研究
5. Clinical outcomes of patients with non-small cell lung carcinoma: a retrospective study. [D] . Decker, Brandee. 2013

机译：非小细胞肺癌患者的临床结局：一项回顾性研究。
6. Bevacizumab plus chemotherapy in nonsquamous non‐small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B [O] . Rintaro Noro, Kunihiko Kobayashi, Jiro Usuki, 2020

机译：贝伐单抗联合化疗治疗非鳞状非小细胞肺癌恶性胸腔积液不受管引流或胸膜固定术控制：II期研究东北日本研究组试验NEJ013B
7. Bevacizumab plus chemotherapy in nonsquamous non‐small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B [O] . Rintaro Noro, Kunihiko Kobayashi, Jiro Usuki, 2020

机译：Bevacizumab Plus化疗在非调节非小细胞肺癌患者的恶性胸膜积液因管排水或胸膜渗透：II期研究东北日本研究组试验NEJ013B

A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A

摘要

著录项

相似文献

相关主题

期刊订阅